CGBIO Reached 94.6 Billion Won in Sales in 2021 Sales Up 133% Over 5 Years, Rapid Operating Profits Increase by 471% Ongoing expansion of R&D investment and overseas exports drive growth trends Performance expected to rise with increased Chinese exports of HA fillers… 2022-04-13 cgbio
CGbio and Kerunxi Medical of China sign 10 billion KRW contract for export of Bongros dental bone graft material Alveolar bone regeneration can reduce bone union time by half compared to heterogeneous bone grafts 10 billion KRW contract for export of… 2022-03-23 cgbio
CGBIO signed an export contract worth KRW 100 billion for “BONGROS”, a bone replacement material with Shanghai Sanyou Medical BONGROS, the main export item of the “NOVOSIS” carrier product. Directly combined with surrounding bone tissue after transplantation into the body Entering… 2022-03-04 cgbio
CGBIO established a corporation in Indonesia and entered the Southeast Asian aesthetic surgery market Established “NEOREGEN” in the form of an aesthetic surgical clinic that provides cosmetic surgery Contributes to perceived quality of life by providing… 2022-03-04 cgbio
Renewed Version of a Wound Therapeutic Instrument exploiting negative pressure, the ‘CURAVAC’, attained an Approval in China Improvement of Convenience in Usage and Reduction in Time for Application of Product to Wounds is Realized through an Overall Amelioration including… 2022-03-02 cgbio
BELUNA, the Bread Massaging Instrument of CGBIO, attained the Certification of Medical Instrument… Propagation of the ‘Solution for Natural Breast’ is expectedly promoted… Based on the Principle of ‘Negative Pressure Wound Therapy’ for inducing Microvascular Generation and Morphological Modification of Organs Targeting the Market of… 2022-03-02 cgbio
CGBIO obtains approval for next-generation ceramic cage ‘NOVOMAX Fusion’ in Australia BGS-7 has proper affinity to a bone and good bone union. Australia has more than 95.5% import dependency on medical devices. CGBIO… 2021-11-11 cgbio
CGBIO gets green light in Mexico for BMP-2 bone graft NOVOSIS NOVOSIS is a medical device consisting of 100% hydroxyapatite ceramic with rhBMP-2. CGBIO aims to pave the way to export NOVOSIS to… 2021-09-29 cgbio
CGBIO attains CE certification of Europe for HA filters ‘CGBIO has acquired two CE markings for hyaluronic acid (HA) fillers, Giselleligne and VOM’, CGBIO officials announced on May 24, 2021. These… 2021-05-24 cgbio
CGBIO receives accreditation from American Association of Tissue Banks (AATB) CGBIO aims to be a global market leader with this AATB accreditation. ‘The Korean renegerative biopharmaceutical firm CGBIO has received accreditation… 2021-03-04 cgbio
